NCT05963867View on ClinicalTrials.gov

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

January 18, 2026

Study Completion Date

July 25, 2026

Conditions
Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Interventions
DRUG

BI 764532

BI 764532

DRUG

[89Zr]Zr-BI 764532

\[89Zr\]Zr-BI 764532

Trial Locations (1)

1081HV

RECRUITING

Amsterdam UMC Locatie VUMC, Amsterdam

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY